LanguageTerm (authority = ISO 639-3:2007); (type = text)
English
Abstract (type = abstract)
Although natural bone grafts including autografts and allografts are widely used in the clinics for the reconstruction of large bone defects, the development of bone graft substitutes (BGSs) continues to be an area of intense research. To apply the concept of tissue engineering in the development of BGSs, osteogenic growth factors and/or stem cells are incorporated into engineered scaffolds to mimic the bone tissue microenvironment. In the Kohn lab, BGSs based on E1001(1k), an intrinsically osteoconductive tyrosine-based polycarbonate, and beta-tricalcium phosphate (β-TCP) nanocrystals, were custom-fabricated (abbreviated as E1001(1k)/β-TCP scaffolds) and tested in various critical size calvarial models in combination with recombinant human bone morphogenetic protein 2 (rhBMP-2). To test the in vivo performance of this type of BGSs in long bone defect reconstruction, comparison study was conducted between E1001(1k)/β-TCP scaffolds and a clinically used β-TCP-based BGS (i.e., chronOS®) in a critical size sheep tibia model, with both constructs carrying a low dose of rhBMP-2 (1.1 mg per defect). It was found that E1001(1k)/β-TCP scaffolds have comparable in vivo performance to chronOS®. More importantly, new bone regenerated in E1001(1k)/β-TCP scaffolds demonstrated a more physiological morphology, indicating ongoing bone remodeling into compact bone tissue.
A critical component in the bone microenvironment is the osteogenic growth factor (GF) phase. Though rhBMP-2 being one of the most studied GFs in the bone regeneration field, adverse effects associated with supraphysiological dosing is reported. Therefore, it is necessary to establish a reliable in vitro-in vivo correlation to determine the proper rhBMP-2 doses as well as to evaluate the efficacy of rhBMP-2 delivery systems. To date, the various study design in examining rhBMP-2 release profile in vitro has precluded comparative analyses. Due to the aforementioned concerns, a systematic evaluation of the most widely used in vitro rhBMP-2 activity assays is reported in Chapter 3. It was found that each model cell line (i.e., W-20-17, MC3T3 and C2C12) has an optimal dose-response range upon rhBMP-2 induction. In addition, a correlation between protein concentration (as measured by enzyme-linked immunosorbent assay) and protein activity (as measured by alkaline phosphatase induction from W-20-17 cells) was established. It was found that the expression system used to produce the rhBMP-2 had the most significant effect on its activity and stability in vitro.
In the previous in vivo studies, E1001(1k)/β-TCP scaffolds have been successfully utilized as carriers of rhBMP-2 to assist the healing process of critical size bone defects. However, the scaffold-only treatments typically demonstrate moderate osteoconductivity in vivo due to the lack of biological cues in synthetic polymers. On the other hand, owning to the unique redox chemistry, chelation capability with metal ions and Michael-type addition from thiols and amines, catechol functionality has triggered great interest in the tissue engineering field. In Chapter 4, E1001(1k) analog polymers were functionalized with catechol side chains for enhanced bioactivity. It was found that the modified polymers were able to support mesenchymal stem cell, human osteoblast and MC3T3 cell growth. In addition, the surface anchoring catechol groups assist nano-sized silver deposition on the polymer surface by immersion-coating in silver nitrate solution, and the Ag-decorated surface has excellent antibacterial properties against Escherichia coli and Staphylococcus aureus. The versatile secondary functionality introduced by catechol modification makes the E1001(1k) analog polymers suitable for multiple bone-related applications.
Subject (authority = LCSH)
Topic
Catechol
Subject (authority = RUETD)
Topic
Chemistry and Chemical Biology
RelatedItem (type = host)
TitleInfo
Title
Rutgers University Electronic Theses and Dissertations
I hereby grant to the Rutgers University Libraries and to my school the non-exclusive right to archive, reproduce and distribute my thesis or dissertation, in whole or in part, and/or my abstract, in whole or in part, in and from an electronic format, subject to the release date subsequently stipulated in this submittal form and approved by my school. I represent and stipulate that the thesis or dissertation and its abstract are my original work, that they do not infringe or violate any rights of others, and that I make these grants as the sole owner of the rights to my thesis or dissertation and its abstract. I represent that I have obtained written permissions, when necessary, from the owner(s) of each third party copyrighted matter to be included in my thesis or dissertation and will supply copies of such upon request by my school. I acknowledge that RU ETD and my school will not distribute my thesis or dissertation or its abstract if, in their reasonable judgment, they believe all such rights have not been secured. I acknowledge that I retain ownership rights to the copyright of my work. I also retain the right to use all or part of this thesis or dissertation in future works, such as articles or books.